PFKFB3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL787879	1.00	18/20
SCHEMBL787888	1.00	18/20
SCHEMBL788412	0.60	18/20
SCHEMBL788169	1.00	17/20
SCHEMBL788549	1.00	17/20
SCHEMBL788563	1.00	17/20
SCHEMBL788842	1.00	17/20
SCHEMBL794120	0.71	17/20
SCHEMBL787695	0.70	17/20
SCHEMBL787910	1.00	16/20
SCHEMBL794619	0.70	16/20
SCHEMBL793936	0.69	16/20
SCHEMBL793735	0.75	15/20
SCHEMBL794820	0.69	15/20
SCHEMBL794692	0.57	15/20
SCHEMBL794309	0.55	15/20
SCHEMBL870167	0.52	15/20
SCHEMBL788594	1.00	14/20
SCHEMBL788203	0.77	14/20
SCHEMBL788512	0.77	14/20

Clinical trials — most relevant to PFKFB3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC	PHASE2	UNKNOWN
Ketohexokinase Inhibition in NAFLD	PHASE2	COMPLETED
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency	PHASE2	UNKNOWN
Acetylcarnitine and Insulin Sensitivity	PHASE2	COMPLETED
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients	PHASE2	UNKNOWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults	PHASE1	RECRUITING
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Effect of Acute Fructose Load in Human	nan	COMPLETED
Dried Fruit and Postprandial Glycemia Trial	nan	UNKNOWN
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology	nan	COMPLETED
Fructose and Glucose and TAS1R2 in Type 1 Diabetes	nan	COMPLETED
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours	nan	RECRUITING
Circadian Brown Adipose Tissue Metabolism	nan	COMPLETED
Early Versus Late FDG-PET/CT in Bladder Cancer	nan	COMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer	nan	UNKNOWN
Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy	nan	COMPLETED
Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer	nan	UNKNOWN
13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment	nan	UNKNOWN
Role and Expression of MXRA5 in Placental Connective Tissue Remodelling in Preeclampsia	nan	UNKNOWN
Diagnostic Performance of 18F-FDG PET/CT in Detecting Distant Metastases in Breast Cancer	nan	NOT_YET_RECRUITING
McArdle Disease Treatment by Ketogenic Diet	nan	COMPLETED
Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer	nan	COMPLETED
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors	nan	RECRUITING
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Diagnostic Significance of Single Center, Open and Prospective Evaluation of 18F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma	nan	WITHDRAWN
Outcome of Use of a Novel Modulator of Oxidative Phosphorylation on Kidney Function in Patients With Progressive Chronic Kidney Disease	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PFKFB3 binder may also engage these)

Protein	Name	Similarity
O35552	—	1.000	O35552 →
Q5R9C1	—	1.000	Q5R9C1 →
Q4R8B6	—	1.000	Q4R8B6 →
P26285	—	1.000	P26285 →
Q9JJH5	—	1.000	Q9JJH5 →
PFKFB2	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2	1.000	landscape →
P70265	—	1.000	P70265 →
P70266	—	1.000	P70266 →
PFKFB4	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4	0.999	landscape →
P49872	—	0.999	P49872 →
PFKFB1	6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1	0.999	landscape →
Q5NVT1	—	0.999	Q5NVT1 →
Q6DTY7	—	0.999	Q6DTY7 →
Q28901	—	0.998	Q28901 →
P07953	—	0.998	P07953 →
P25114	—	0.998	P25114 →
Q91348	—	0.995	Q91348 →
Q91309	—	0.994	Q91309 →
Q21122	—	0.990	Q21122 →
P32604	—	0.990	P32604 →
Q9NWZ5	—	0.989	Q9NWZ5 →
Q91YL3	—	0.988	Q91YL3 →
Q6DNF7	—	0.987	Q6DNF7 →
B4NBB0	—	0.986	B4NBB0 →
Q14562	—	0.985	Q14562 →
B0XDC4	—	0.985	B0XDC4 →
P54936	—	0.984	P54936 →
Q80UN9	—	0.984	Q80UN9 →
Q8VYB2	—	0.984	Q8VYB2 →
Q8BRK8	—	0.984	Q8BRK8 →